

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

| | Year Ended December 31, | |
|--------------------------------------|----------------------------|------------|
| | 2021 | 2020 |
| Grant and collaboration revenue | \$ 385 | \$ 1,823 |
| Operating expenses: | | |
| Research and development | 15,554 | 2,444 |
| General and administrative | 3,577 | 2,196 |
| | 19,131 | 4,640 |
| Loss from operations | (18,746) | (2,817) |
| Other income (expense), net | 176 | (141) |
| Net loss | \$ (18,570) | \$ (2,958) |
| Net loss per common share | \$ (3.04) | \$ (2.14) |
| Weighted averages shares outstanding | 6,099,933 | 1,383,523 |

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

| | December 31, | |
|--|--------------|-----------|
| | 2021 | 2020 |
| Assets | | |
| Cash and cash equivalents | \$ 11,424 | \$ 9,884 |
| Other current assets | 205 | 351 |
| Total current assets | 11,629 | 10,235 |
| Property and other assets | 168 | 159 |
| Total assets | \$ 11,797 | \$ 10,394 |
| Liabilities and stockholders' equity | | |
| Total liabilities | \$ 7,435 | \$ 825 |
| Stockholders' equity | 4,362 | 9,569 |
| Total liabilities and stockholders' equity | \$ 11,797 | \$ 10,394 |
| Common shares outstanding | 6,381,541 | 3,832,892 |